{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 0f9441d3-f4fd-4217-ab6b-6f1d3192f387 --><h2>Metronidazole</h2><!-- end field 0f9441d3-f4fd-4217-ab6b-6f1d3192f387 -->","summary":"","htmlStringContent":"<!-- begin item 64039e88-b943-4c4b-b595-485ef6d785d3 --><!-- end item 64039e88-b943-4c4b-b595-485ef6d785d3 -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"7871650d-a8b8-5140-ac00-0ba65c72081f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a6024ecd-3cf9-4114-a11a-a9360108ec0d --><h3>What are the contraindications and cautions?</h3><!-- end field a6024ecd-3cf9-4114-a11a-a9360108ec0d -->","summary":"","htmlStringContent":"<!-- begin item 01310f00-05b7-48d3-9ed1-a9360108ea9b --><!-- begin field c864ea9a-16d6-4cc9-997f-a9360108ec0d --><ul><li><strong>Do not prescribe metronidazole to people with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe metronidazole with caution to people with:</strong><ul><li>Severe liver disease or hepatic encephalopathy — prescribe a third of the daily dose once daily.</li><li>Active or chronic severe peripheral and central nervous system disease — there is a risk of neurological aggravation.</li><li>Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure (including cases with a fatal outcome with very rapid onset after treatment initiation in people with Cockayne syndrome) have been reported with products containing metronidazole for systemic use (oral and suppositories).<ul><li>Only prescribe metronidazole after careful benefit-risk assessment and only if no alternative treatment is available.</li><li>Perform liver function tests just prior to the start of treatment, during treatment, and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached.</li><li>Advise the person to immediately report any symptoms of potential liver injury to their doctor and stop taking metronidazole.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field c864ea9a-16d6-4cc9-997f-a9360108ec0d --><!-- end item 01310f00-05b7-48d3-9ed1-a9360108ea9b -->","subChapters":[]},{"id":"46a692e5-30dd-5bdb-8426-49aebda92630","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6d69e115-7424-40bd-90ff-a93601091481 --><h3>What are the adverse effects?</h3><!-- end field 6d69e115-7424-40bd-90ff-a93601091481 -->","summary":"","htmlStringContent":"<!-- begin item d1335591-7cbd-4353-ad0e-a936010911c6 --><!-- begin field c8f8c23f-5999-4bfd-8f04-a93601091481 --><ul><li><strong>Adverse effects of metronidazole include: </strong><ul><li><strong>Very rare</strong> — arthralgia, myalgia, ataxia, darkening of urine, dizziness, drowsiness, headache, pruritus, rash, erythema multiforme, hepatitis, jaundice, leucopenia (on prolonged or intensive therapy), pancytopenia, thrombocytopenia, pancreatitis, peripheral neuropathy (on prolonged or intensive treatment), psychotic disorders, transient epileptiform seizures (on prolonged or intensive treatment), and visual disturbances.</li><li><strong>Frequency not known</strong> — anorexia, aseptic meningitis, furred tongue, gastrointestinal disturbances, nausea, vomiting, oral mucositis, taste disturbances, and optic neuropathy.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field c8f8c23f-5999-4bfd-8f04-a93601091481 --><!-- end item d1335591-7cbd-4353-ad0e-a936010911c6 -->","subChapters":[]},{"id":"15be7171-a7b6-5018-8861-c793e8f41ecd","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 183b265e-9d94-4fbb-97f5-a936010b4a1b --><h3>What are the drug interactions?</h3><!-- end field 183b265e-9d94-4fbb-97f5-a936010b4a1b -->","summary":"","htmlStringContent":"<!-- begin item 3241a926-3d82-4ecd-8c19-a936010b4978 --><!-- begin field d33572ec-ee6e-4ece-ac75-a936010b4a1b --><ul><li><strong>Drug interactions of metronidazole include:</strong><ul><li><strong>Alcohol</strong> — some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might</em> experience this reaction if they drink alcohol whilst taking metronidazole. Alcohol should be avoided during treatment with metronidazole and for at least 48 hours afterwards.</li></ul></li><li><strong>Anticoagulants</strong> — the anticoagulant effects of warfarin and acenocoumarol can be markedly increased by metronidazole. There is no interaction with heparin. <ul><li>Monitor the international normalized ratio (INR) if concurrent treatment is indicated, and adjust the anticoagulant dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding, and advise them on when to seek medical help.</li></ul></li><li><strong>Ciclosporin</strong> — people receiving concurrent metronidazole and ciclosporin are at risk of elevated serum ciclosporin levels.<ul><li>When co-administration of metronidazole and ciclosporin is necessary, monitor serum ciclosporin and creatinine levels closely.</li></ul></li><li><strong>Lithium</strong> — raised lithium levels accompanied by evidence of possible renal damage has been reported in people treated simultaneously with lithium and metronidazole.<ul><li>Before starting metronidazole in a person taking lithium, seek specialist advice about tapering or stopping lithium treatment.</li><li>If concurrent treatment is unavoidable, closely monitor plasma concentrations of lithium, creatinine, and electrolytes.</li></ul></li><li><strong>Phenobarbital or phenytoin</strong> — people receiving phenobarbital or phenytoin metabolize metronidazole at a much greater rate than normal, thereby reducing the half-life to approximately 3 hours. In addition, both metronidazole and phenytoin can increase the risk of peripheral neuropathy.</li></ul></li><li><strong>Oral hormonal contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of metronizadole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>metronidazole</strong><strong><strong>,</strong> </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field d33572ec-ee6e-4ece-ac75-a936010b4a1b --><!-- end item 3241a926-3d82-4ecd-8c19-a936010b4978 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}